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Loss-of-Function Mutations in WDR73 Are
Responsible for Microcephaly and Steroid-Resistant
Nephrotic Syndrome: Galloway-Mowat Syndrome
Estelle Colin,1,2,15 Evelyne Huynh Cong,3,4,15 Ge´raldine Mollet,3,4 Agne`s Guichet,1 Olivier Gribouval,3,4
Christelle Arrondel,3,4 Olivia Boyer,3,4,5 Laurent Daniel,6 Marie-Claire Gubler,3,4,5 Zelal Ekinci,7
Michel Tsimaratos,8 Brigitte Chabrol,9 Nathalie Boddaert,4,10 Alain Verloes,11 Arnaud Chevrollier,1,2
Naig Gueguen,1,2 Vale´rie Desquiret-Dumas,1,2 Marc Ferre´,1,2 Vincent Procaccio,1,2 Laurence Richard,12
Benoit Funalot,12 Anne Moncla,13 Dominique Bonneau,1,2,16 and Corinne Antignac3,4,14,16,*
Galloway-Mowat syndrome is a rare autosomal-recessive condition characterized by nephrotic syndrome associated with microcephaly
and neurological impairment. Through a combination of autozygosity mapping and whole-exome sequencing, we identifiedWDR73 as
a gene in whichmutations cause Galloway-Mowat syndrome in two unrelated families.WDR73 encodes aWD40-repeat-containing pro-
tein of unknown function. Here, we show that WDR73 was present in the brain and kidney and was located diffusely in the cytoplasm
during interphase but relocalized to spindle poles and astral microtubules during mitosis. Fibroblasts from one affected child and
WDR73-depleted podocytes displayed abnormal nuclear morphology, low cell viability, and alterations of the microtubule network.
These data suggest that WDR73 plays a crucial role in the maintenance of cell architecture and cell survival. Altogether,WDR73muta-
tions cause Galloway-Mowat syndrome in a particular subset of individuals presenting with late-onset nephrotic syndrome, postnatal
microcephaly, severe intellectual disability, and homogenous brain MRI features. WDR73 is another example of a gene involved in a
disease affecting both the kidney glomerulus and the CNS.Introduction
Galloway-Mowat syndrome (GMS [MIM 251300]) is a rare
autosomal-recessive disorder characterized by the combi-
nation of nephrotic syndrome (NS) and various CNS ab-
normalities.1 Since the first report by Galloway andMowat
in 1968,2 more than 60 cases of GMS have been reported.3
Several case reports and studies on small series describing
the clinical and histopathological features of GMS have
revealed the clinical heterogeneity of this condition.
Although some authors have tried to categorize GMS
according to clinical presentation,4 no classification is
currently accepted for this disease. The consistentmorpho-
logical hallmark is microcephaly, which is often present
at birth (primary microcephaly) but might also develop
postnatally (secondary microcephaly). Major brain abnor-
malities include cerebral atrophy and neural-migration
defects, such as agyria, microgyria, or polymicrogyria.
These structural brain abnormalities are associated with se-
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The Americanhalf of all cases. Renal manifestations of GMS range from
isolated proteinuria to overt, steroid-resistant NS, which
rapidly progresses to end-stage kidney disease (ESKD) after
a few months. Although NS is typically detected in the
first months of life, later onset during childhood (44–
198 months) has been reported in a few cases.5–7 The ana-
tomopathological lesions observed in kidney biopsies
include minimal changes, focal segmental glomeruloscle-
rosis (FSGS) that might be of the collapsing type, and
diffuse mesangial sclerosis, which is sometimes difficult
to distinguish from FSGS.8 The prognosis of GMS is poor,
and most affected children die before the age of 6 years.
Although a growing number of genes have been impli-
cated in syndromic and nonsyndromic hereditary NS,
the molecular basis of GMS is currently unknown. Given
its clinical heterogeneity, it is likely that this syndrome is
genetically heterogeneous. In a previous study,9 an anal-
ysis of candidate genes encoding proteins of the glomer-
ular basement membrane (LAMB2 [MIM 150325] and
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Figure 1. Identification of WDR73 Mu-
tations, Gene Structure, and Protein
Structure
(A) Pedigrees of families A and B. The
affected status is indicated by filled sym-
bols, and the allele status is given below
each tested individual. Representative
chromatograms show the homozygous
c.129 T>G (p.Tyr43*) and c.766dupC
(p.Arg256Profs*18) mutations and the
wild-type allele. Red arrows indicate the
position of the nucleotide changes. Abbre-
viations are as follows: het, heterozygous;
and hom, homozygous.
(B) Schematic overview of the eight exons
(black boxes) of human WDR73 and of
the six WD40 repeats (green hexagons)
predicted in WDR73. Asterisks (for the
gene) and red diamonds (for the protein)
denote the two mutations described in
this article.
(C) Model of residues 73–370 of human
WDR73 (GenBank AAF28942.1). WDR73
is shown as a rainbow-spectrum cartoon
showing the six-bladed b sheets. Blades
are numbered 1–6, and the direction of
the polypeptide chain is indicated by a
color ramp (N-terminal in blue and C-ter-
minal in red) along the length of the
ribbon.[MIM 135630], ITGA3 [MIM 605025], and ACTN4 [MIM
604638]) failed to detect any causative mutation in a
cohort of 18 GMS-affected individuals.
In this study, we used whole exome sequencing (WES)
to identify WDR73 mutations in two families affected
by GMS. We demonstrated that the localization of the
WDR73 product, a WD40-repeat-containing protein, was
cell-cycle dependent. WDR73 was diffuse in the cytosol
during interphase and enriched at the spindle poles and
microtubule asters during mitosis. Functional studies in fi-
broblasts from one affected child and in WDR73-depleted
podocytes revealed that loss of WDR73 led to defects in
cell survival and microtubule organization, and these
might explain the dual neurologic and renal phenotype
in this subset of individuals with GMS.Subjects and Methods
Human Studies
Genomic DNAwas isolated from blood or from cultured skin fibro-
blasts by standard procedures. Written informed consent was ob-
tained from each subject involved in this study or from parents
of subjects under 18 years of age. The study protocol was approved
by two institutional review boards (Comite´ de Protection des Per-
sonnes Ile de France II and Comite´ d’E´thique duCentre Hospitalier
Universitaire d’Angers) in accordance with French law. Pedigrees
of the families involved in this study are shown in Figure 1A.
Autozygosity Mapping and WES
Although no consanguinity was known in family A, we hypothe-
sized that the parents could be related because of their close
geographical origins. We performed a genome-wide search with638 The American Journal of Human Genetics 95, 637–648, DecembSNP microarrays (Illumina Human 660W-Quad ADN v.1.C) to
identify shared runs of homozygosity (ROHs) in the two affected
children (II-3 and II-4, both from family A). Data were interpreted
with Illumina GenomeStudio v.2010.3 and CNVPartition v.3.1.6
(Illumina Genotyping v.1.8.4 Genome Viewer v.1.8). Analyses
were mapped to the human reference genome sequence (UCSC
Genome Browser assembly GRCh37/hg19).
WES was performed in individual II-3 from family A (Figure 1A)
at Integragen (Evry). Whole-exome capture was performed with
the SureSelect Human All Exon Kit v.2 (Agilent Technologies).
The enriched library was then sequenced on an Illumina HiSeq
2000 (2 3 75 bases). Images were analyzed and the bases were
determined with the pipeline Illumina RTA v.1.14 (CASAVA 1.8).
Reads were mapped to the human reference genome sequence
(UCSC Genome Browser assembly GRCh37/hg19). We subse-
quently applied autozygome filtration to identify homozygous
mutations in coding sequences within the ROHs previously de-
tected by SNP-microarray analysis. Screening for WDR73 muta-
tions in additional affected individuals and segregation validation
were performed by Sanger sequencing. PCR primers (Table S1,
available online) were designed with the program Primer3 accord-
ing to RefSeq accession number NM_032856.2.Plasmids, Cell Culture, and Establishment of
Lentiviral Cell Lines
The lentiviral vector pLenti-GIII-CMV-HA, which contains the hu-
manWDR73 coding sequence (GenBank clone accession number
BC063392), was purchased from Applied Biological Materials. Two
hemagglutinin (HA) tags were added to the WDR73 N terminus
with the QuickChange site-directed mutagenesis kit according to
the manufacturer’s (Stratagene’s) protocol. This construct, used
for rescuing the WDR73-depleted podocyte phenotype, is called
wild-type (WT) later in the text. Constructs were verified by Sanger
sequencing. Lentiviral particles containing this construct wereer 4, 2014
produced by the lentivector production facility Structure Fe´de´ra-
tive de Recherche BioSciences Gerland-Lyon Sud (UMS3444/
US8). Two small hairpin RNAs (shRNAs) targeting the 30 UTR of
the human WDR73 mRNA (clone IDs TRCN0000135232 and
TRCN0000135695 from the RNAi Consortium) in the lentiviral
vector pLKO.1 were purchased from Thermo Scientific. Lentiviral
particles were produced in human embryonic kidney 293T cells
as previously described.10 Stably WDR73-depleted human podo-
cyte cell lines were obtained by transduction with both types of
shWDR73 lentiviral particles and subsequent puromycin selection
(2 mg/ml).
Primary skin fibroblasts, herein called A-II-4 fibroblasts, were ob-
tained from individual II-4 from family A (Figure 1A) andwere sub-
sequently grown in OPTIMEM medium supplemented with 10%
fetal bovine serum, sodium pyruvate, glutamine, fungizone, and
penicillin and streptomycin (all from Life Technologies) at 37C
with 7% CO2.
A conditionally immortalized human podocyte cell line, devel-
oped by transfection with the temperature-sensitive mutant
(tsA58) of the SV40-T-antigen-encoding gene, was kindly provided
by M.A. Saleem (University of Bristol, Southmead Hospital, Bris-
tol). In brief, the cells proliferated at the permissive temperature
of 33C, whereas growth arrest and differentiation were induced
by incubation at the nonpermissive temperature of 37C for
14 days. Cells were grown with 7% CO2 in RPMI 1640 medium
supplemented with 10% fetal bovine serum, insulin-transferrin-
selenium, glutamine, and penicillin and streptomycin (all from
Life Technologies).Antibodies and Immunoblotting
Antibodies used for immunoblotting and immunofluorescence
were mouse anti-GAPDH (Millipore), anti-HA (Covance), anti-
a-tubulin (Sigma-Aldrich), rabbit anti-WDR73 (Sigma-Aldrich),
goat anti-synaptopodin, anti-lamin B, and anti-g tubulin (Santa
Cruz), and Alexa Fluor-conjugated annexin V (Life Technologies).
Total cell lysate was extracted with lysis buffer (50 mM Tris-HCl,
150 mM NaCl, 0.5% sodium deoxycholate, 2 mM EDTA, 1%
Triton X-100, and 0.1% SDS). A total of 100 mg of protein was
loaded onto a 4%–20% acrylamide gel (Biorad) or a 12% gel, and
immunoblotting was carried out with the indicated antibodies as
previously described.11Immunochemistry and Immunofluorescence
Five-micron-thick sections of formalin-fixed paraffin-embedded
samples of human infant brain (3 months old) and fetal kidney
(25 weeks of gestation) were obtained. Slides were dewaxed either
in toluene or in Bioclear solution (Bio-Optica) for brain or kidney
sections, respectively, and then immersed in water. Samples were
boiled for 25 min in a water bath in antigen-retrieval solution (Da-
koCytomation) and subsequently cooled in the same solution at
room temperature. Endogenous peroxidase activity was quenched
by treatment in 0.3% H2O2 for 30 min. The sections were preincu-
bated in normal serum diluted in PBS (10%) for 30min for the pre-
vention of nonspecific binding. The samples were then incubated
with the anti-WDR73 primary antibody overnight at 4C. The
bound antibodies were visualizedwith an avidin-biotin peroxidase
kit (VECTASTAIN, Vector Laboratories), and 3.30-diaminobenzi-
dine tetrahydrochloride (DAB) was used as a chromogen (DAB
Peroxidase Substrate Kit, Vector Laboratories). Sections were coun-
terstained with Mayer’s hematoxylin, mounted, and observed
with a Nikon optic microscope.The AmericanFibroblasts and podocytes were plated on Lab-Tek Chamber
Slides and on coverslips coated with rat-tail collagen type I (Corn-
ing), respectively. After 48 hr of culture, cells were fixed in either
cold 100% methanol or 4% paraformaldehyde (PFA). PFA-fixed
cells were treated with 50 mM NH4Cl. Cells were incubated with
a blocking solution (PBS, 1% BSA, and 0.1% tween 20) for 1 hr
prior to primary antibody hybridization. For tissue sections, slides
were treated as described above before antibody incubation. Cells
and tissues were then probed with appropriate Alexa Fluor-conju-
gated secondary antibodies (Life Technologies), and nuclei were
stained with Hoechst (Life Technologies).
For assessment of microtubule repolymerization, human podo-
cytes were incubated with 30 mM of nocodazole (Sigma) for 4 hr at
33C or 37C for undifferentiated or differentiated podocytes,
respectively. Cells were then washed with PBS, incubated at
33C or 37C, and fixed after 0, 5, or 60 min. Finally, immunoflu-
orescence was carried out as described above.
For the annexin V (Life Technologies) assay, cells were first incu-
bated with annexin V in 10 mM HEPES, 140 mM NaCl, and
25 mM CaCl2 before PFA fixation, and then nuclei were stained
with Hoechst. Confocal images were obtained with a Leica TCS-
SP8 microscope, and posttreatment analysis was performed with
Image J.
Cell-Proliferation Assay
Fibroblasts were seeded into 96-well plates at 8,000 cells per well in
triplicate and were allowed to attach for 24 hr. Cell proliferation
was assessed with the CellTiter 96 Aqueous Non-Radioactive Cell
Proliferation Assay (MTT) (Promega) according to the manufac-
turer’s protocol after 24, 48, 72, 96, and 120 hr of culture.
WDR73 Modeling
The structure ofWDR73was predicted with theWD40-Repeat Pro-
tein Structure Predictor (WDSP) 12,13 on the basis of WDR73
sequence from GenBank accession number AAF28942.1 (residues
73–370). The structure was manually inspected, and figures were
drawn in MacPyMOL (Schro¨dinger).
Statistical Analysis
Results are presented as means 5 SEM or SD. Statistical analysis
was performed with the Student’s t test for pairwise comparisons
and the ANOVA test for comparisons involving three or more
groups. Analysis was carried out with GraphPad Prism. A p value
of <0.05 was considered statistically significant (*p < 0.05; **p <
0.01, ***p < 0.005). All experiments were performed at least three
times.Results
WDR73 Mutations in GMS
We performed autozygosity mapping combined with WES
in a Moroccan family (family A) with two affected children
to investigate the genetic basis of GMS. Both children
developed secondary microcephaly and severe neurolog-
ical impairment, and one also developed nephrotic syn-
drome (individual II-3 in family A; Figure 1A; Table 1).
Genome-wide analysis with SNP arrays revealed that the
affected siblings from family A share only one common
ROH, which is 4.3 Mb in length and located on chromo-
some 15. This region contains 24 genes, one of which isJournal of Human Genetics 95, 637–648, December 4, 2014 639
Table 1. Clinical and Pathological Phenotypes of Affected Individuals
Family A Family B
II-3 II-4 II-3
Sex male male male
Age of onset of
proteinuria
NS at 5 years no proteinuria 6 g/g at 8 years, 0.7 g/g at 13 years
Renal lesions collapsing FSGS, podocyte hypertrophy no (at 7 years) FSGS, podocyte hypertrophy
Age of ESKD 5 years no (at 7 years) no (at 13 years)
Neurological
features
secondary microcephaly (1 SD at birth,
3 SDs at 5 years), peripheral hypertonia,
axial hypotonia (diagnosed at 4 months),
nystagmus, epileptic spasms, ID
secondary microcephaly (þ1 SD at birth,
2.5 SDs at 2 years), peripheral and axial
hypotonia (diagnosed at 4 months),
epileptic spasms, ID
head circumference at 2 SDs at




cerebellar atrophy, thin corpus callosum cerebellar atrophy, subtentorial atrophy cerebellar atrophy, thin corpus
callosum, subtentorial atrophy,
ventricular dilation
Other features facial dysmorphy, abnormal visual
evoked potentials, optic atrophy, death
at 5 years
facial dysmorphy, optic atrophy facial dysmorphy, abnormal visual
evoked potentials, optic atrophy
Abbreviations are as follows: ESKD, end-stage kidney disease; FSGS, focal segmental glomerulosclerosis; and ID, intellectual disability.
aNo cranial circumference available at birth.referenced in OMIM (ZNF592 [MIM 613624]). Given the
number of coding sequences in this ROH, we performed
WES in one affected child (individual II-3 from family
A). The average read coverage of chromosome 15 was
643, and 77% of targeted bases were covered at least by
25 reads. A nonsense WDR73 mutation (c.129T>G
[p.Tyr43*]; RefSeq NM_032856.2) was the only homozy-
gous damaging variant within the ROH (Figure S1). Next,
we screenedWDR73mutations in a cohort of 30 unrelated
individuals with microcephaly and neurological impair-
ment associated with glomerular lesions or isolated pro-
teinuria. In one child from a consanguineous Turkish
family, we detected another homozygous frameshift muta-
tion inWDR73 (c.766dupC [p.Arg256Profs*18]). Both mu-
tations segregated with the disease (Figure 1A), and neither
is referenced in the NHLBI Exome Variant Server or in
dbSNP. In addition, we screened for mutations in WDR73
in a group of 26 individuals with microcephaly but
without obvious renal involvement or any mutation in
known primary microcephaly-associated genes; however,
we found no mutations.
WDR73 is predicted to encode a protein containing six
WD40 motifs, which have an average score of 66.34 and
an estimated accuracy of 89.5% in WDSP12,13 (Figures 1B
and 1C). The p.Tyr43* alteration truncates the protein pre-
cociously and is located upstream of all of the WD40 re-
peats, whereas the p.Arg256Profs*18 mutant is expected
to contain four WD40 repeats (Figure 1B).
Phenotype of Individuals Carrying homozygous
WDR73 Mutations
All three affected children presented with a similar
neurological phenotype consisting of severe intellectual
disability and secondary microcephaly diagnosed at 4 or640 The American Journal of Human Genetics 95, 637–648, Decemb5months of age (Table 1). Two of the children also suffered
from epilepsy. In all affected individuals, brain MRI
showed major cerebellar atrophy without brainstem
anomalies, a thin corpus callosum, moderate sustentorial
atrophy, and mild ventricular dilation. No apparent
myelin or gyration defects were observed (Figure 2A; Table
1). Affected individuals II-3 from family A and II-3 from
family B (Figure 1A) developed NS, which was detected at
5 and 8 years of age, respectively. Individual II-3 from fam-
ily A presented with steroid resistant NS at 5 years of age,
rapidly developed chronic renal insufficiency, and eventu-
ally died within a month. Individual II-3 in family B had
normal renal function at the last examination at 13 years
of age. Kidney biopsies were performed in both of these
children. In individual II-3 in family A, tissue sections re-
vealed severe collapsing FSGS, characterized by the diffuse
retraction of the glomerular tufts surrounded by hypertro-
phic podocytes and the focal development of segmental
sclerotic lesions. Foci of interstitial fibrosis and tubular di-
lations were associated with glomerular lesions (Figure 2B;
Table 1). Lesions were less severe in individual II-3 in fam-
ily B (Figure 1A), which is consistent with normal renal
function in this child. However, glomerular tufts were
lined by hypertrophic and focally vacuolated podocytes,
and FSGS lesions affecting a small percentage of glomeruli
were present alongwithmoderate tubulointerstitial lesions
(Figure 2B; Table 1). Individual II-4 from family A
(Figure 1A) had no proteinuria and had normal renal func-
tion at the last follow-up examination at the age of 7 years.
WDR73 Localization in the Human Kidneys and Brain
According to GeneCards, WDR73 RNA is ubiquitously ex-
pressed in normal human tissues, including the brain
and kidneys. We first sought to determine precisely theer 4, 2014
Figure 2. Neuroimaging and Renal Pathological Analysis
(A) MRI features of three affected individuals with GMS. Sagittal T1 (a, d, and e) and T2 (b) images are shown. Microcephaly with no
gyration defect, a thin corpus callosum, and cortical and cerebellar (arrows) atrophy without brainstem anomalies were common in
all affected individuals. Axial T2 images (c and f) are shown. Ventricular dilations with moderate subtentorial atrophy were observed
in individuals II-4 in family A and II-3 in family B.
(B) Kidney sections of individuals with WDR73 mutations. Individual II-3 in family A showed (a) a marked collapse of the glomerular
tufts associated with podocyte hypertrophy (arrow; trichrome-safranin stain; 633magnification) and (b) the presence of a FSGS lesion
surrounded by a layer of enlarged podocytes. The adjacent capillary loops are retracted, and the capillary lumen is small (arrowhead;
methenamine-silver stain; 1003magnification). Individual II-3 from family B showed (c) diffuse podocyte hypertrophy and periglomer-
ular fibrosis and large vacuoles in some cells (arrow;methenamine-silver stain; 633magnification) and (d) the presence of an FSGS lesion
(arrowhead; trichrome-safranin stain in light green; 1003 magnification).localization of WDR73 in human fetal kidney and infant
brain by performing immunochemistry staining on tissue
sections. In fetal kidney, where all stages of nephrogenesis
are present, we observed strong staining in immature po-
docytes from the S-shaped-body stage to the capillary-
loop stage (Figure 3A, left and middle panels). In contrast
to the persistent strong staining of the podocyte foot-pro-
cess marker synaptopodin, WDR73 labeling was weaker at
the late stages than at the early stages of glomerular matu-
ration. In mature glomeruli, WDR73 had a punctuated dis-
tribution at the periphery of the glomerular tuft, outside
the linear labeling of synaptopodin. This dissociated distri-
bution suggests that WDR73 is present in the cell body of
mature podocytes (Figure 3A, right panel). We also de-
tected an intense punctuated WDR73 labeling in mature
tubules (Figure 3A, right panel). In human infant brain,
WDR73 was found in a large variety of cells. In the cere-
bellum, WDR73 immunostaining was strong in Purkinje
cells and their projecting axons (Figure 3B, left panel),
in the deep cerebellar nuclei (data not shown), and in
pyramidal neurons of the cerebral cortex (Figure 3B, mid-
dle panel). In the white matter, WDR73 appeared to be
mainly present in astrocytes, but not in oligodendrocytes
(Figure 3B, right panel). Finally, endothelial cells of cere-
bral capillaries also displayed a high amount of WDR73
(Figure 3B, right panel). We observed a similar localization
pattern in adult brain (data not shown).The AmericanWDR73 Subcellular Localization throughout the Cell
Cycle and Its Role in Cell Viability
In control fibroblasts, WDR73 displayed weak and diffuse
staining within the cytoplasm during interphase, whereas
during mitosis, it strongly accumulated at the spindle
poles and microtubule asters and later in the cleavage
furrow (Figure 4). We observed a similar pattern in a hu-
man immortalized podocyte cell line that is commonly
used as a cellular model for studying glomerulopathy14
(Figure S2).
We sought to elucidate the function of WDR73; there-
fore, we characterized the cellular phenotype of fibroblasts
from individual II-4 in family A and podocytes stably ex-
pressing shRNA against WDR73. In both cell lines, the
abundance of WDR73 was drastically lower than that in
the control cell lines (Figure S3A).
Interestingly, in A-II-4 fibroblasts, we observed striking
abnormalities in the size and shape of the nuclei, such
as budding or flecking nuclei or multinucleated cells
(Figure 5A). Given that these nuclear abnormalities
strongly suggest a defect in cell viability,15 we conducted
a cell-proliferation assay and found that cell survival was
lower in A-II-4 fibroblasts than in control cells
(Figure 5B). This difference could have been due to either
a defect in cell proliferation or a higher rate of apoptosis.
Annexin V labeling showed that the rate of apoptosis
was higher in A-II-4 fibroblasts than in control cellsJournal of Human Genetics 95, 637–648, December 4, 2014 641
Figure 3. WDR73 Localization in Kidneys
and Brain
(A) Immunofluorescence in normal hu-
man kidney sections shows the localiza-
tion of WDR73 (in green) and synaptopo-
din (in red). During kidney development,
strong labeling of WDR73 was observed
from the S-shaped-body stage (white ar-
row) to the capillary-loop stage (arrow-
head) and decreased along glomerulus
maturation.
(B) Immunoperoxidase staining of endoge-
nous WDR73 in the infant CNS. WDR73
localized to the cell body of Purkinje cells
in the cerebellum (left panel, arrows), in
pyramidal neurons in the cerebral cortex
(middle panel, arrows), and in their projec-
ting axons (left and middle panels, arrow-
heads). In the white matter (right panel),
WDR73 antibodies stained the cell body
of astrocytes (arrows) and their cell pro-
cesses (black arrowheads) and also endo-
thelial cells of cerebral capillaries (white
arrowheads). WDR73 was not detected in
oligodendrocytes (red arrowheads).
Scale bars represent 20 mm.(Figure 5C).WDR73-depleted podocytes also presented nu-
clear abnormalities, mainly multilobulated nuclei. This
phenotype was rescued by reintroduction of the wild-
type protein (Figure 5A). However, no cell-survival defect
was observed, which could have been due to the immortal-
ization of podocytes (Figure S3B).
Role of WDR73 in Organization of the Microtubule
Network
Gerlitz et al.16 showed that newly synthesized microtu-
bules anchored at the centriole generate pressure in the
nucleus and thus transiently disturb its shape in physiolog-
ical conditions. Once the microtubule network is reorgan-
ized, the nucleus returns to its usual shape. We thus
wondered whether dysregulation of the microtubule
network could be responsible for the abnormal nuclear642 The American Journal of Human Genetics 95, 637–648, December 4, 2014shape in WDR73-depleted podocytes
(Figure 6, upper panel). We treated
undifferentiated podocytes with no-
codazole to depolymerize microtu-
bules and monitored microtubule
growth and nuclear morphology.
After complete depolymerization, nu-
clear shape was restored, and cyto-
solic tubulin aggregates appeared in
WDR73-depleted podocytes (Figure 6,
middle panel). After 1 hr of repolyme-
rization, the ratio of abnormally
shaped nuclei to normal nuclei was
higher in WDR73-depleted cells than
in control cells (Figure 6, lower panel).
In addition, WDR73-depleted cells
displayed dense and disorganizedmicrotubule aggregates around the nucleus, whereas con-
trol cells showed well-spread and -distributed microtubule
cables (Figure 6, lower panel).
We and others have shown that differentiated podocytes
are delicate cells, and the maintenance of their architec-
ture requires fine regulation of microtubule and actin
dynamics.17–19 Therefore, we also studied the organization
of the microtubule network in differentiated WDR73-
depleted podocytes. Whereas control and wild-type-re-
expressing cells were spread with a partial localization of
WDR73 adjacent to microtubule cables, the depleted
cells clearly showed a loss of WDR73 along the microtu-
bules and presented an abnormal shape (Figure 7A), also
found in A-II-4 fibroblasts (Figure S4A). Similar to that in
control cells, the presence of synaptopodin in differenti-
ated WDR73-depleted podocytes suggests that WDR73
Figure 4. WDR73 Localization during the
Cell Cycle
Immunolabeling of WDR73 (in red), g-
tubulin (in cyan), a marker of the centri-
oles, and a-tubulin (in green) in control
fibroblasts. During interphase, a weak cyto-
solic staining of WDR73 was observed.
However, during mitosis (from prophase
to anaphase), WDR73 relocalized to micro-
tubule asters and the cleavage furrow. Scale
bars represent 10 mm.deficiency does not impair podocyte differentiation
(Figure S4B). We then treated differentiated podocytes
with nocodazole as described above and examined
the polymerization of microtubules into the aster after
5 min of recovery. The diameter of the asters was smaller
in WDR73-depleted podocytes than in control cells
(Figure 7B, left and middle panels). This alteration, which
is a hallmark of a delay in microtubule polymerization,20
was rescued by re-expression of the wild-type construct
(Figure 7B, right panel). Altogether, these data suggest a
crucial role for WDR73 in the regulation of microtubule
dynamics and organization during interphase.Discussion
Through autozygosity mapping, WES, and subsequent
genotyping in a small cohort of individuals with GMS,
we identified two truncating homozygous mutations in
WDR73 in two families. The detection of mutations in a
small subset of GMS-affected individuals (2 out of 31)
further substantiates the idea that GMS is a genetically het-The American Journal of Human Generogeneous disease (an idea that was
already suspected from its clinical het-
erogeneity). The main clinical mani-
festations in these two families were
postnatal microcephaly diagnosed
within the first year of life, marked
cerebellar atrophy, severe intellectual
disability, and late-onset NS. However,
an important interfamilial and intra-
familial variability was observed for
the severity of the renal phenotype:
one affected child (individual II-4 in
family A) showed no symptoms at
the age of 7 years. This is reminiscent
of what was observed in some families
affected by early-onset NS and muta-
tions in PLCE1 (MIM 608414).21–23
Furthermore, no additional mutations
in genes known to be mutated in he-
reditary NS were found in these
affected individuals, which could not
explain the clinical heterogeneity of
the renal phenotype. Conversely, wetested WDR73 in 26 individuals with microcephaly
without renal involvement and did not find anymutation,
suggesting that WDR73 is not involved in isolated micro-
cephaly. Nevertheless, we suggest that physicians should
screen for proteinuria in children with a neurological
phenotype similar to that described above. Altogether,
our data show that mutations in WDR73 cause GMS.
WDR73 encodes a protein containing WD40 repeats,
which are motifs of approximately 40–60 amino acid resi-
dues usually ending with Trp-Asp (WD).24 Each WD40
repeat folds into a four-stranded antiparallel b sheet blade.
These blades often assemble into domains containing a
seven-bladed propeller called theWD40 domain. These do-
mains act as platforms for protein assembly, making them
hubs in many cell-signaling networks.24 Several genes en-
coding WD40-domain proteins have already been impli-
cated in human genetic disorders.25–27WDR73 is predicted
to harbor six WD40 repeats leading to an incomplete six-
bladed propeller protein. Some proteins, such as Seh1
and Sec, only have a six-bladed propeller, which interacts
with another blade from a donor protein—Nup85 and
Nup145, respectively—to form a b propeller with sevenetics 95, 637–648, December 4, 2014 643
Figure 5. Phenotype of WDR73-
Depleted Podocytes and Fibroblasts
(A) Hoechst staining in fibroblasts (left
panel) and podocytes (right panel). A-II-4
fibroblasts and WDR73-depleted podo-
cytes displayed alterations in nuclear
morphology, including budding, multilo-
bulation (white arrows), shrinkage, or frag-
mentation. For generating the graphical
quantification of the number of nuclear al-
terations, 100 nuclei from ten random
fields in each condition were observed
and classified as having either a normal
or an abnormal nuclear shape. The Stu-
dent’s t test was used for comparing dif-
ferences between A-II-4 and control
fibroblasts. The mean 5 SEM is shown (*
p < 0.05; **p < 0.01). Scale bars represent
20 mm.
(B) Graph showing the results of the color-
imetric cell-proliferation assay (MTT) in fi-
broblasts. The viability of A-II-4 cells was
significantly lower than that of control
cells. The Student’s t test was used for
comparing differences between A-II-4 and
control fibroblasts. The mean 5 SEM is
shown (*p < 0.05; **p < 0.01).
(C) Immunolabeling of annexin V shows a
higher rate of apoptosis in A-II-4 fibroblasts
than in control fibroblasts. Scale bars repre-
sent 10 mm.blades.28 We can therefore hypothesize that WDR73 re-
quires the association of another partner to form a com-
plete standard propeller. WDR73 mutations, leading to
the deletion of WD40 repeats, might prevent the assembly
of this b propeller structure, thus impairing the recruit-
ment of its partners.
Our experiments in various cell models clearly suggest
a role for WDR73 in cell survival and microtubule regula-
tion. We have shown that WDR73 is localized in the cyto-
plasm during interphase and then accumulates at the
spindle poles and microtubule asters during mitosis. This
behavior resembles that of proteins encoded by genes
mutated in primary microcephaly, namely CENPJ (MIM
609279),29 ASPM (MIM 605481),30,31 and WDR62 (MIM
613583).25,27,32 Therefore, it is tempting to speculate that
WDR73, similar toWDR62, is involved inmitosis in neural
precursors during embryonic life. However, the head
circumference of individuals at birth appeared normal,
suggesting that the proliferation of neuronal precursors
was normal; instead, we hypothesize that WDR73 has an
important role in neuronal cell survival. Indeed, the cere-
bellar atrophy and the secondary microcephaly observed
in these children could be due to a high rate of cells
entering apoptosis, as observed in A-II-4 fibroblasts.
In addition, the microtubule-polymerization defects
observed in the cell lines and the localization of WDR73
in a large variety of neurons and their projecting axons
in both the cerebral and cerebellar cortex suggest that644 The American Journal of Human Genetics 95, 637–648, DecembWDR73 is also involved in the organization of neuronal
and axonal microtubule networks.33 Indeed, fine regula-
tion of the microtubule network is crucial for the comple-
tion of brain development and is required for dendritic and
axonal arborization and growth, myelination, and synap-
togenesis during the first years of life in both the cere-
bellum and the brain cortex.34
Our findings in the kidney support the idea that
WDR73 plays a role in the regulation of the microtubule
network, which is consistent with recent data on heredi-
tary NS and FSGS. Indeed, genetic studies have identified
>20 NS- and FSGS-associated genes, which mainly encode
proteins expressed in podocytes.35 This highly differenti-
ated cell has an octopus-like shape with microtubule-
enriched primary processes and interdigitated actin-rich
secondary foot processes bridged by the slit diaphragm.
These genes mainly encode slit-diaphragm components
and actin-cytoskeleton regulators that confer to the podo-
cyte its precise shape and plasticity. Mutations in these
genes result in foot-process effacement driven by the
global reorganization of the actin cytoskeleton and sub-
sequent protein leakage in the urine. More recently, the
identification of mutations in genes encoding micro-
tubule regulators, such as INF2 (MIM 610982),18 and
TTC21B (MIM 612014),19 also suggests that the integrity
of the slit diaphragm depends on microtubules, which
are crucial for the maintenance of cell architecture
and protein trafficking. Interestingly, the distincter 4, 2014
Figure 6. Effect of WDR73 Invalida-
tion on Microtubule Polymerization
and Nuclear Shape in Undifferentiated
Podocytes
Immmunolabeling of a-tubulin (in green)
and lamin (in red), a marker of the nuclear
envelope, before and after nocodazole
treatment. After microtubule depolymer-
ization induced by 4 hr incubation with
nocodazole (T0), the shape of the nucleus
in WDR73-depleted cells became similar
to that in control cells, and microtubule
aggregates within the cytosol were
observed (white arrows). After microtubule
repolymerization (T60), WDR73-depleted
cells contained a nonhomogenous reparti-
tion of microtubules cables (arrow head)
that did not properly diffuse within the
cytosol, and the nucleus became multilo-
bulated. A graph at T0 and T60 shows the
number of multilobulated cells during
the microtubule-regrowth assay. The Stu-
dent’s t test was used for comparing dif-
ferences between WDR73-depleted and
control podocytes. The mean 5 SEM
is shown (ns, not significant; *p < 0.05;
**p < 0.01). Scale bars represent 20 mm.immunostaining patterns of WDR73 and the actin-associ-
ated protein synaptopodin suggest that WDR73 preferen-
tially localizes to the microtubule-enriched primary foot
processes and not to the actin-rich secondary foot
processes.
Although podocytes and neurons are highly differenti-
ated cells, which are very dissimilar in terms of structure
and function, both cell types share many common bio-
logical features.36–38 Neurons and podocytes are both
organized into amain cell body, giving rise tomultiple pro-
jections that subsequently form axons and dendrites in
neurons and primary foot processes in podocytes with
the same atypical microtubule polarity.39 In addition,
several structural and regulatory proteins—such as synap-
topodin,40 Huntingtin-interacting protein 1, neurofascin,
and olfactomedin-like 2a38—are specifically localized in
both neurons and podocytes. Other similarities between
podocytes and neurons include the presence of func-
tional-neuron-like synaptic vesicles in podocytes41 and
the importance of glutamatergic signaling, which in podo-
cytes contributes to the integrity of the glomerular-filtra-
tion barrier.42 However, there are still very few examples
of genes in which mutations have been identified
as responsible for genetic diseases impairing both the
glomerulus and the nervous system. Mutations in INF2The Americanaffect podocytes, Schwann cells, and peripheral nerve
axons, leading to a disease associating an intermediate
neuropathy with impaired glomerular function. WDR73
is another example of a gene in which mutations result
in this dual phenotype, providing additional evidence of
the existence of common molecular processes of develop-
ment and maintenance in the glomerulus and the nervous
system.36
In conclusion, we have demonstrated that mutations
in WDR73 are responsible for GMS. The implication of
WDR73 in the regulation of the microtubule network
during the cell cycle suggests that it plays a crucial role in
the development and maturation of the nervous system
and in the maintenance of the proper function and integ-
rity of glomerular filtration. The identification of proteins
interacting with WDR73 and/or mutations in other
genes associated with GMS will shed more light on the
role of WDR73 and the pathophysiology of this very rare
condition.Supplemental Data
Supplemental Data include four figures and one table and can be
found with this article online at http://dx.doi.org/10.1016/j.
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Figure 7. Effect of WDR73 Depletion on Microtubule Polymeri-
zation and Cell Shape in Differentiated Podocytes
(A) Immunostaining ofWDR73 (in red) and a-tubulin (in green) in
differentiated podocytes. WDR73 localized adjacent to some
microtubule cables (arrow heads). WDR73 depletion was associ-
ated with abnormal morphology and altered WDR73 localization,
which was rescued by the wild-type protein.
(B) Nocodazole treatment in differentiated podocytes was con-
ducted before immunolabeling with g-tubulin (in red) and
a-tubulin (in green) antibodies. After 5 min of microtubule re-
growth, WDR73-depleted podocytes displayed a delay in microtu-
bule polymerization, which was restored by reintroduction of the
wild-type protein.
Scale bars represent 20 mm.Acknowledgments
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